Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions.

Current atherosclerosis reports - 3 Jun 2020

Hussain Aliza, Ballantyne Christie M, Saeed Anum, Virani Salim S

Abstract excerpt

PURPOSE OF REVIEW: This review focuses on recent evidence examining the role triglycerides (TG) and triglyceride-enriched lipoproteins (TGRL) play in atherosclerotic cardiovascular disease (ASCVD). It also provides a succinct overview of current and future TG-lowering therapies for ASCVD risk reduction. RECENT FINDINGS: Epidemiological and Mendelian randomization studies have consistently shown that TGRL are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiopoietin-Like Protein 3
Share to Angiopoietin-like Proteins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Apolipoprotein C-III

Share to Eicosapentaenoic Acid

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hypertriglyceridemia

Share to Lipoproteins

Share to Risk Reduction Behavior

Source

Identifiers

PMID: 32494924
DOI: 10.1007/s11883-020-00846-8

Genes

TG
ANGPTL3
APOC3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions.PMID 32494924Read ↗

Do triglyceride-lowering drugs decrease risk of cardiovascular disease?Semantic proximity Read ↗

Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction.Semantic proximity Read ↗

Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic StudiesSemantic proximity Read ↗

Genetics of hypertriglyceridemia and atherosclerosisSemantic proximity Read ↗

Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology.Semantic proximity Read ↗

Addressing dyslipidemic risk beyond LDL-cholesterol.Semantic proximity Read ↗

Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease.Semantic proximity Read ↗

Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease.Semantic proximity Read ↗

ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases.Semantic proximity Read ↗

Remnant cholesterol - The transition from biomarker to risk factor.Semantic proximity Read ↗

Updates in Small Interfering RNA for the Treatment of DyslipidemiasSemantic proximity Read ↗

Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular eventsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.